Buy & Sell Microchip Technology Inc. (MCHP) – Microchip Technology Inc. Price Today
Aura AI Summary
Key Stats
- $50.65BMarket Cap
- TechnologySector
- -19.53%3M Drawdown
- $55.94BEnterprise Value
- 1.95%Dividend Yield
- 63 daysTypical Hold Time
Microchip Technology Inc. (MCHP) is currently valued at a market capitalization of $50.65B, with an enterprise value of $55.94B. Over the past 52 weeks, Microchip Technology Inc. has traded between a low of $49.02 and a high of $102.97, highlighting its annual price range. Over the past three months, Microchip Technology Inc. has recorded a drawdown of -19.53%, reflecting recent price volatility. Microchip Technology Inc. offers a dividend yield of 1.95%, with the most recent dividend of $0.46 paid on 22 May 26. On average, investors hold Microchip Technology Inc. for approximately 63 days, indicating typical investor behavior on the platform.
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Most Recent News
Microneedle drug delivery market to double to $14.37B by 2035, driven by pain-free therapies and vaccine tech.
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...

Akeso to present over 40 oncology studies at ASCO 2026, highlighting key bispecific antibody trials.
Akeso, Inc. announced it will present more than 40 clinical studies of its oncology portfolio at the 2026 ASCO Annual Meeting, including a Late-Breaking Abstract in the Plenary Session. Key data will focus on its bispecific antibodies cadonilimab and...

Hansa Biopharma to present positive 12-month Phase 3 kidney transplant trial results at American Transplant Congress.
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...
